A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

This study tests whether secukinumab (a biologic drug targeting the IL-17 pathway) at 300 mg effectively reduces symptoms in Chinese adults with active ankylosing spondylitis — an inflammatory disease that primarily affects the spine and causes chronic back pain and stiffness. You may be eligible if... - You are 18 to 80 years old - You have a confirmed diagnosis of ankylosing spondylitis (AS) meeting the modified New York criteria - Your disease is active: pain score and BASDAI score both at or above 4 out of 10 - At least two NSAIDs have not worked well enough for you over 4 or more weeks You may NOT be eligible if... - You have previously used any biologic therapy for spondyloarthritis - You have previously used a JAK inhibitor (like tofacitinib or baricitinib) - You use opioid pain medications (excluding acetaminophen/codeine combinations) - You have another type of inflammatory arthritis (e.g., rheumatoid arthritis, lupus) - Your blood counts or kidney/liver function values are outside acceptable ranges Talk to your doctor to see if this trial is right for you.